Medical Library | Shanghai Oncology and Innovative Treatment Series
Shanghai Chest Hospital, affiliated with Shanghai Jiao Tong University, is one of China's major centers for thoracic oncology, lung cancer medicine, minimally invasive thoracic surgery, esophageal surgery, and mediastinal tumor care. Its clinical programs span targeted therapy, immunotherapy, anti-angiogenic combinations, robotic surgery, neoadjuvant treatment, and recurrence-risk modeling.
This Medical Library review examines four representative teams and technology directions based on the 2025–2026 information provided. It also explains how CMCS can help international patients prepare their records and communicate with thoracic oncology specialists in Shanghai.
1. Medical Oncology: Registration-Grade Trials in Advanced Non-Small Cell Lung Cancer
Lead: Professor Lu Shun
Focus: First-line targeted therapy, immunotherapy and bispecific strategies for advanced NSCLC, EGFR-mutated lung cancer, and squamous cell carcinoma.
Professor Lu Shun's program is described as one of China's most productive sources of registration-grade Phase III lung cancer evidence. Its research spans molecularly defined EGFR-mutated disease and broader populations of advanced NSCLC, including lung squamous cell carcinoma. Patients looking for general background can also read our Lung Cancer and Advanced Oncology Treatment in Shanghai Medical Library guide.
Key 2025–2026 milestones
- HARMONi-6: At the June 2026 ASCO plenary session, ivonescimab plus chemotherapy was reported head-to-head against tislelizumab plus chemotherapy as first-line treatment for lung squamous cell carcinoma. The reported reduction in the risk of death was 34%, and the regimen received NMPA approval in August 2026.
- AENEAS 2: Published in The Lancet Oncology in June 2026, this study evaluated first-line alflutinib plus chemotherapy in EGFR-mutated lung cancer.
The HARMONi-6 result is notable because plenary ASCO presentations are highly selective and can influence global discussion of a treatment strategy. The clinical question is not simply whether a new immunotherapy is active, but whether it improves outcomes compared with an established first-line option in a defined patient population.
For EGFR-mutated NSCLC, the AENEAS 2 program illustrates the continued search for better first-line combinations. Patients should confirm the exact EGFR alteration, understand whether the treatment is approved for that mutation and treatment line, and discuss the added benefit and additional toxicity of chemotherapy.
Team profile: A high-output lung cancer clinical research program connecting molecularly targeted treatment, immunotherapy combinations, and registration-grade Phase III evidence.
2. Respiratory and Critical Care Medicine: Moving toward Chemotherapy-Sparing Combinations
Leads: Honorary Professor Han Baohui and Director Zhong Hua
Focus: Driver-negative and PD-L1-positive NSCLC, maintenance treatment for extensive-stage small-cell lung cancer, and rare EGFR mutations.
The respiratory oncology program represents a second major clinical research line at Shanghai Chest Hospital. Its work emphasizes combinations that may reduce reliance on conventional chemotherapy in selected patients, while also exploring anti-angiogenic and immune-based approaches.
Key 2025–2026 milestones
- CAMPASS: Published in The Lancet Oncology in March 2026, the study compared bemosumab plus anlotinib with pembrolizumab monotherapy as first-line treatment for patients with driver-negative, PD-L1-positive NSCLC. The reported progression-free survival exceeded 11 months.
- Extensive-stage small-cell lung cancer: Anlotinib plus durvalumab maintenance was reported in Nature Communications in May 2026.
The drug name “bemosumab” follows the English rendering used for the antibody in the supplied material. Before treatment, patients should confirm the exact product name, target, regulatory status, biomarker requirements, and approved indication with the treating team.
The underlying strategy is to combine immune activation and vascular-targeted treatment, with the aim of extending disease control while tailoring therapy to the tumor's molecular and immune profile. In extensive-stage small-cell lung cancer, maintenance therapy is particularly important because disease can progress quickly after initial response.
Patients should ask how response will be monitored, how immune-related and vascular toxicities will be managed, and whether a combination is being used as an approved treatment or within a clinical study.
Team profile: A major thoracic oncology program focused on chemotherapy-sparing strategies, immunotherapy, anti-angiogenic combinations, and difficult-to-treat small-cell lung cancer.
3. Thoracic Surgery: Robotic Evidence for Esophageal Cancer
Lead: Professor Li Zhigang
Focus: Minimally invasive and robotic esophageal surgery, with neoadjuvant chemotherapy and immunotherapy.
Esophageal cancer surgery is technically demanding because it may involve the chest, abdomen, and upper digestive tract. The treatment plan often includes neoadjuvant systemic therapy, careful lymph-node management, reconstruction, and long-term nutritional and functional support.
According to the information provided, the RAMIE study, published in The Lancet Gastroenterology & Hepatology in April 2026, was the world's first prospective multicenter randomized controlled trial comparing robotic-assisted minimally invasive esophagectomy with thoracoscopic esophagectomy. The reported five-year overall survival was approximately 13 percentage points higher in the robotic group.
This result is important because it evaluates robotic surgery through prospective comparative evidence rather than relying only on technical feasibility or single-center experience. However, the applicability of the result still depends on patient selection, tumor stage, neoadjuvant treatment, surgeon experience, hospital volume, complication rates, and postoperative recovery.
Patients may also review our Esophageal Cancer Surgery article featuring Dr. Li Zhigang and our overview of Thoracic Surgery at Shanghai Chest Hospital when preparing for a surgical consultation.
Questions to ask about robotic esophagectomy
- Is the tumor location and stage suitable for a robotic approach?
- What neoadjuvant treatment is recommended before surgery?
- How does the team assess the likelihood of a complete cancer resection and adequate lymph-node clearance?
- What are the risks of anastomotic leakage, pulmonary complications, nutritional problems, and reflux?
- How will swallowing, weight, diet, and quality of life be managed after surgery?
Team profile: A thoracic surgery program that has helped establish randomized evidence for robotic esophageal cancer surgery in China.
4. Thoracic and Mediastinal Tumors: Neoadjuvant Treatment before Reoperation
Lead: Professor Gu Zhitao, with Professor Fang Wentao as a mentor
Focus: Thymoma, thymic carcinoma, and mediastinal germ-cell tumors.
Locally advanced thymic tumors can involve major vessels, the pericardium, lungs, or other mediastinal structures. Immediate surgery may not always be the safest or most effective first step. The team has proposed an integrated model in which selected patients receive neoadjuvant treatment followed by reassessment and reoperation.
The information provided states that the integrated “neoadjuvant treatment followed by reoperation” model for locally advanced thymic tumors was systematized in February 2026. The team also participated in the ChART recurrence-prediction model, which aims to support risk assessment after treatment.
This type of strategy depends on accurate imaging, pathology, assessment of resectability, response to preoperative treatment, and a surgical team able to manage complex mediastinal anatomy. A tumor that becomes technically operable is not automatically a tumor for which surgery will provide the best overall outcome.
Patients should ask whether the tumor is a thymoma, thymic carcinoma, or another mediastinal tumor, whether a biopsy is required before systemic therapy, what the neoadjuvant goal is, and how the team will decide whether to proceed to surgery.
Team profile: A mediastinal tumor program helping formalize a response-adapted pathway for locally advanced thymic disease.
5. How to Interpret These Thoracic Oncology Advances
The four programs address different clinical questions:
- Advanced NSCLC: whether new immunotherapy and targeted combinations can improve first-line survival.
- Driver-negative and PD-L1-positive disease: whether immune and anti-angiogenic strategies can extend disease control while reducing chemotherapy reliance in selected settings.
- Esophageal cancer: whether robotic surgery can improve long-term outcomes compared with thoracoscopic surgery when delivered by experienced teams.
- Thymic and mediastinal tumors: whether neoadjuvant treatment can make complex tumors more safely and completely resectable.
Patients should distinguish among an academic presentation, a published trial, regulatory approval, and routine clinical availability. The most relevant question is always whether the evidence applies to the patient's histology, molecular profile, stage, previous treatment, overall health, and treatment goals.
6. How CMCS Helps International Patients Discuss Innovative Treatment with Specialists
For an international patient seeking lung, esophageal, or mediastinal cancer care in Shanghai, the first step is usually to match the clinical question with the right oncology or thoracic surgery team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize pathology reports, immunohistochemistry, molecular testing, PD-L1 results, imaging, bronchoscopy or endoscopy reports, operative notes, previous treatment records, medication history, treatment response, laboratory results, and current symptoms. For overseas patients, these records can be arranged into a concise English medical summary for the specialist.
CMCS can help patients prepare focused questions such as:
- Is the proposed targeted therapy, immunotherapy, bispecific, or combination approved for this tumor type and treatment line?
- Does the patient's EGFR or other driver mutation, PD-L1 level, or pathology support the proposed treatment?
- For surgery, would neoadjuvant therapy improve the chance of a complete resection?
- Is robotic surgery appropriate for this patient's anatomy, stage, and overall condition?
- For a thymic or mediastinal tumor, what findings would determine whether to proceed from neoadjuvant treatment to surgery?
- What are the expected benefits, main toxicities, alternatives, and monitoring requirements?
- Is the proposed treatment approved, part of a clinical trial, off-label, or still investigational?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the treatment and follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient and the treating medical team. CMCS does not independently select a medicine, operation, or clinical trial. Its role is to help the patient bring complete information to the right specialist and ensure that the indication, evidence, risks, alternatives, access, and monitoring plan are discussed clearly.
To learn more about oncology consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Shanghai Chest Hospital teams reviewed here are advancing thoracic oncology through registration-grade lung cancer trials, chemotherapy-sparing combinations, randomized evidence for robotic esophageal surgery, and response-adapted treatment of complex mediastinal tumors. Together, these programs show how modern thoracic care is moving toward more precise patient selection and stronger comparative evidence.
For patients, the goal is not to pursue every new technology, but to identify the option that best fits the diagnosis, molecular profile, stage, previous treatment, health status, and personal goals. This article was prepared from the team and program information provided for editorial use. Research milestones, approval status, and clinical data should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 comentarios